Trade Report: Today, vTv Therapeutics Inc. (VTVT) Given “Buy” Rating at HC Wainwright

Today, vTv Therapeutics Inc. (VTVT) Given “Buy” Rating at HC Wainwright

vTv Therapeutics Inc. (NASDAQ:VTVT)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday.

VTVT has been the topic of several other research reports. Zacks Investment Research lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 12th. Piper Jaffray Cos. restated an “overweight” rating and set a $24.00 target price on shares of vTv Therapeutics in a research report on Saturday, October 15th. Finally, Canaccord Genuity restated a “buy” rating and set a $15.00 target price on shares of vTv Therapeutics in a research report on Friday, August 19th. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $15.70.

Shares of vTv Therapeutics (NASDAQ:VTVT) traded up 0.53% on Tuesday, hitting $5.70. The stock had a trading volume of 30,441 shares. vTv Therapeutics has a 52 week low of $4.69 and a 52 week high of $7.70. The company has a 50-day moving average of $5.97 and a 200 day moving average of $5.96. The company’s market capitalization is $55.25 million.

A number of hedge funds and other institutional investors have recently made changes to their positions in VTVT. Bank of New York Mellon Corp raised its position in shares of vTv Therapeutics by 7.6% in the third quarter. Bank of New York Mellon Corp now owns 21,278 shares of the company’s stock valued at $153,000 after buying an additional 1,504 shares during the last quarter. BlackRock Investment Management LLC increased its stake in shares of vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock valued at $161,000 after buying an additional 5,596 shares during the period. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock valued at $180,000 after buying an additional 822 shares during the period. Kennedy Capital Management Inc. bought a new stake in shares of vTv Therapeutics during the first quarter valued at approximately $282,000. Finally, State Street Corp increased its stake in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock valued at $488,000 after buying an additional 22,983 shares during the period. Institutional investors and hedge funds own 12.65% of the company’s stock.

vTv Therapeutics Company Profile

Related posts

Leave a Comment